• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

异体基因严重急性呼吸系统综合征冠状病毒 2 特异性 T 细胞治疗免疫功能低下患者持续性 2019 冠状病毒病。

Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2-Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients.

机构信息

Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.

出版信息

Clin Infect Dis. 2023 Sep 11;77(5):696-702. doi: 10.1093/cid/ciad233.

DOI:10.1093/cid/ciad233
PMID:37078720
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10495124/
Abstract

We administered severe acute respiratory syndrome coronavirus-2 viral-specific T cells (VSTs) under emergency investigational new drug applications to 6 immunocompromised patients with persistent coronavirus disease 2019 (COVID-19) and characterized clinical and virologic responses. Three patients had partial responses after failing other therapies but then died. Two patients completely recovered, but the role of VSTs in recovery was unclear due to concomitant use of other antivirals. One patient had not responded to 2 courses of remdesivir and experienced sustained recovery after VST administration. The use of VSTs in immunocompromised patients with persistent COVID-19 requires further study.

摘要

我们根据紧急调查性新药申请，为 6 名患有持续性 2019 冠状病毒病（COVID-19）的免疫功能低下患者施用了严重急性呼吸综合征冠状病毒 2 型病毒特异性 T 细胞（VST），并对临床和病毒学反应进行了特征描述。3 名患者在其他疗法失败后出现部分缓解，但随后死亡。2 名患者完全康复，但由于同时使用了其他抗病毒药物，VST 在康复中的作用尚不清楚。1 名患者在接受了 2 个疗程的瑞德西韦治疗后没有反应，在接受 VST 治疗后持续康复。在持续性 COVID-19 免疫功能低下患者中使用 VST 需要进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95f2/10495124/23375f54f449/ciad233f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95f2/10495124/23375f54f449/ciad233f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95f2/10495124/23375f54f449/ciad233f1.jpg

相似文献

1
Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2-Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients.异体基因严重急性呼吸系统综合征冠状病毒 2 特异性 T 细胞治疗免疫功能低下患者持续性 2019 冠状病毒病。
Clin Infect Dis. 2023 Sep 11;77(5):696-702. doi: 10.1093/cid/ciad233.
2
Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.免疫功能低下宿主持续性 SARS-CoV-2 感染的晚期抗病毒治疗效果。
J Virol. 2024 Sep 17;98(9):e0090524. doi: 10.1128/jvi.00905-24. Epub 2024 Aug 29.
3
Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.新型冠状病毒对造血干细胞移植和嵌合抗原受体 T 细胞治疗受者的影响。
Transplant Cell Ther. 2021 Sep;27(9):796.e1-796.e7. doi: 10.1016/j.jtct.2021.07.005. Epub 2021 Jul 10.
4
A phase I/II study of adoptive SARS-CoV-2-specific T cells in immunocompromised hosts with or at risk of severe COVID-19 infection.一项关于在患有严重COVID-19感染或有感染风险的免疫功能低下宿主中采用SARS-CoV-2特异性T细胞的I/II期研究。
Cytotherapy. 2024 Oct;26(10):1170-1178. doi: 10.1016/j.jcyt.2024.05.014. Epub 2024 May 18.
5
Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.免疫功能低下患者持续性或复发性严重急性呼吸综合征冠状病毒 2 感染的 2 种抗病毒药物和单克隆抗体三联疗法。
Clin Infect Dis. 2023 Jul 26;77(2):280-286. doi: 10.1093/cid/ciad181.
6
Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature review.造血干细胞移植受者高危 SARS-CoV-2 感染的有效病毒特异性 T 细胞治疗：初步病例研究和文献复习。
Geroscience. 2024 Feb;46(1):1083-1106. doi: 10.1007/s11357-023-00858-7. Epub 2023 Jul 6.
7
[Hematopoietic stem cell transplantation during the COVID-19 pandemic with reference to EBMT recommendation].[参照欧洲血液与骨髓移植学会（EBMT）建议，在2019冠状病毒病大流行期间进行造血干细胞移植]
Rinsho Ketsueki. 2021;62(2):106-114. doi: 10.11406/rinketsu.62.106.
8
Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.第三方及患者特异性供体来源的病毒特异性T细胞在儿童和青年造血干细胞移植后病毒感染管理中显示出相似的疗效和安全性。
Transplant Cell Ther. 2023 May;29(5):305-310. doi: 10.1016/j.jtct.2023.01.027. Epub 2023 Feb 3.
9
SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.SARS-CoV-2 感染免疫功能低下患者：体液免疫与细胞免疫。
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000862.
10
Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib.芦可替尼治疗的异基因造血干细胞移植患者中新型 SARS-CoV-2 感染减弱。
Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):720-723. doi: 10.1016/j.clml.2020.06.014. Epub 2020 Jun 25.

引用本文的文献

1
Allogeneic 'off-the-shelf' SARS-CoV-2-specific adoptive T-cell therapy for refractory viral infection and end organ disease.用于难治性病毒感染和终末器官疾病的异基因“现成可用”的严重急性呼吸综合征冠状病毒2特异性过继性T细胞疗法。
Clin Transl Immunology. 2025 Jun 10;14(6):e70038. doi: 10.1002/cti2.70038. eCollection 2025.
2
Optimization of hypo-alloimmunogenic multispecific CAR-T and SARS-CoV-2-specific T cells for off-the-shelf adoptive cell therapy.用于现成过继性细胞疗法的低同种异体免疫原性多特异性嵌合抗原受体T细胞和严重急性呼吸综合征冠状病毒2特异性T细胞的优化
Mol Ther Methods Clin Dev. 2025 Apr 10;33(2):101462. doi: 10.1016/j.omtm.2025.101462. eCollection 2025 Jun 12.
3

本文引用的文献

1
Immunocompromised Patients with Protracted COVID-19: a Review of "Long Persisters".患有持续性新冠病毒感染的免疫功能低下患者：“长期感染者”综述
Curr Transplant Rep. 2022;9(4):209-218. doi: 10.1007/s40472-022-00385-y. Epub 2022 Nov 12.
2
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients.异体、现成的、针对 SARS-CoV-2 的 T 细胞（ALVR109）治疗高危患者的 COVID-19。
Haematologica. 2023 Jul 1;108(7):1840-1850. doi: 10.3324/haematol.2022.281946.
3
Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use.
Virus-Specific T-Cell Therapy for the Management of Viral Infections in the Immunocompromised.
用于免疫功能低下患者病毒感染管理的病毒特异性T细胞疗法
Transfus Med Hemother. 2024 Sep 25;52(1):5-26. doi: 10.1159/000540961. eCollection 2025 Feb.
4
Off-the-shelf allogeneic natural killer cells for the treatment of COVID-19.用于治疗新冠肺炎的现成同种异体自然杀伤细胞。
Mol Ther Methods Clin Dev. 2024 Oct 28;32(4):101361. doi: 10.1016/j.omtm.2024.101361. eCollection 2024 Dec 12.
5
COVID-19-related Pneumonitis in Immunocompromised Patients: Reviewing Clinical Features and Management Approaches.免疫功能低下患者的新型冠状病毒肺炎相关肺炎：临床特征与管理方法综述
J Community Hosp Intern Med Perspect. 2024 Sep 9;14(5):63-72. doi: 10.55729/2000-9666.1399. eCollection 2024.
6
A Robust Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T- and B-Cell Response Is Associated With Early Viral Clearance in SARS-CoV-2 Omicron-Infected Immunocompromised Individuals.在 SARS-CoV-2 奥密克戎感染免疫功能低下个体中，强大的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）特异性 T 细胞和 B 细胞反应与早期病毒清除相关。
J Infect Dis. 2024 Oct 16;230(4):e860-e871. doi: 10.1093/infdis/jiae306.
7
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19.下一代治疗方法：针对新冠病毒的免疫疗法和先进疗法。
Heliyon. 2024 Feb 19;10(5):e26423. doi: 10.1016/j.heliyon.2024.e26423. eCollection 2024 Mar 15.
8
Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature review.造血干细胞移植受者高危 SARS-CoV-2 感染的有效病毒特异性 T 细胞治疗：初步病例研究和文献复习。
Geroscience. 2024 Feb;46(1):1083-1106. doi: 10.1007/s11357-023-00858-7. Epub 2023 Jul 6.
使用索托维单抗后新冠病毒德尔塔变异株中的耐药突变
N Engl J Med. 2022 Apr 14;386(15):1477-1479. doi: 10.1056/NEJMc2120219. Epub 2022 Mar 9.
4
The T cell immune response against SARS-CoV-2.针对 SARS-CoV-2 的 T 细胞免疫应答。
Nat Immunol. 2022 Feb;23(2):186-193. doi: 10.1038/s41590-021-01122-w. Epub 2022 Feb 1.
5
ALVR109, an off-the-shelf partially HLA matched SARS-CoV-2-specific T cell therapy, to treat refractory severe COVID-19 pneumonia in a heart transplant patient: Case report.ALVR109，一种即用型部分 HLA 匹配的 SARS-CoV-2 特异性 T 细胞疗法，用于治疗心脏移植患者难治性严重 COVID-19 肺炎：病例报告。
Am J Transplant. 2022 Apr;22(4):1261-1265. doi: 10.1111/ajt.16927. Epub 2021 Dec 27.
6
Severe Acute Respiratory Syndrome Coronavirus 2 Viremia Is Associated With Coronavirus Disease 2019 Severity and Predicts Clinical Outcomes.严重急性呼吸综合征冠状病毒 2 病毒血症与 2019 年冠状病毒病严重程度相关，并预测临床结局。
Clin Infect Dis. 2022 May 3;74(9):1525-1533. doi: 10.1093/cid/ciab686.
7
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.现成的EBV特异性T细胞免疫疗法用于移植后利妥昔单抗难治性EBV相关淋巴瘤。
J Clin Invest. 2020 Feb 3;130(2):733-747. doi: 10.1172/JCI121127.
8
Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial.自体过继性 T 细胞疗法治疗实体器官移植受者复发性或耐药性巨细胞病毒并发症：一项单臂开放标签 I 期临床试验。
Clin Infect Dis. 2019 Feb 1;68(4):632-640. doi: 10.1093/cid/ciy549.
9
Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections.用于难治性感染“现成可用”过继性治疗的病毒特异性T细胞库。
Bone Marrow Transplant. 2016 Sep;51(9):1163-72. doi: 10.1038/bmt.2016.17. Epub 2016 Apr 4.
10
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.多中心研究使用第三方储存的病毒特异性 T 细胞治疗造血干细胞移植后严重病毒感染。
Blood. 2013 Jun 27;121(26):5113-23. doi: 10.1182/blood-2013-02-486324. Epub 2013 Apr 22.